Renaissance Capital logo

GPCR News

Here's what the top-performing IPOs of 2023 tell us about 2024

RYZB

Get ready for a bevy of biotech IPOs. The 30 IPOs that raised $100 million or more in 2023 currently average a strong 25% return from offer, thanks to solid first day gains (+14%) that have built in the aftermarket (+9%). Biotechs make up half of the top 10 best-performing sizable IPOs from last year. While a few biotechs are also among 2023’s...read more

CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO, as it seeks to overcome weak trading from recent biotech listings

CRGX

Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry. CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the year's fourth-largest biotech IPO to date. Its proposed deal size would put it in the largest 5% of biotech IPOs in the past...read more

Pessimism over Fed policy and geopolitical tensions topple year's large IPOs; here are the deals that have weathered the recent turmoil

GPCR

After a strong rally through July, markets have treaded water for the past three months as investors grow pessimistic about the possibility of near-term rate cuts, against a backdrop of political gridlock in the US and a new war abroad. The year's sizable IPOs have slowly declined in the past few months' volatility, and the percentage trading above issue has fallen to its lowest...read more

Large IPOs line up despite latest challenges

ABVX

Despite geopolitical turmoil and a major flop from Birkenstock (BIRK) rocking the IPO market last week, a handful of large issuers are lining up to go public. Two sizable IPOs launched on Monday, joined by two notable initial filings. ...read more